A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compares the side effect profile of risperidone vs. paroxetine in treatment of panic attacks and compares response rates of risperidone vs. paroxetine in treatment of panic attacks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Males and females, ages 18-55.
Ability to sign an informed consent
Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
HAM-A score >17
Alcohol or substance abuse within the last 6 months
Current diagnosis of Obsessive-Compulsive Disorder
Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
Use of antipsychotic medications over the two months preceding enrollment in the study
Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
Previous adverse reaction to risperidone or paroxetine.